Belite Bio On A Tear As It Approaches Key Regulatory Submissions [Seeking Alpha]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Seeking Alpha
Tinlarebant showed statistically significant slowing of lesion growth in Stargardt Disease Type 1 and solid tolerability, addressing a major unmet need, but risks remain. Key risks include the FDA possibly requiring a second Phase III study, pricing uncertainty, and the EU's acceptance of the DRAGON study's primary endpoint of slower lesion growth. The path forward in geography atrophy is unclear, as pricing would be very different for this indication. I value BLTE at ~$165/share today, with meaningful upside if regulatory and clinical milestones are met, but current risk/reward is less compelling after the recent rally. Ivan-balvan/iStock via Getty Images The market has definitely started to care more about Belite Bio ( BLTE ) in the last few months, as the shares of this ophthalmology-focused biotech have risen roughly 150% since late September. The stock has likewise started attracting the attention of larger sell-side This article was written by Analyst's Disclosure
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)GlobeNewswire
- Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.MarketBeat
- Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)GlobeNewswire
- Belite Bio (NASDAQ:BLTE) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $195.00 price target on the stock.MarketBeat
- Belite Bio (NASDAQ:BLTE) was given a new $191.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
BLTE
Earnings
- 11/10/25 - Miss
BLTE
Sec Filings
- 1/30/26 - Form S-8
- 1/27/26 - Form 6-K
- 12/10/25 - Form SCHEDULE
- BLTE's page on the SEC website